## Industry/Academia Translational Oncology Symposium Agenda

November 16, 2007

Location: Goldberg Auditorium, Moores UCSD Cancer Center Time: 8:00am - 6:00pm

## Organizers:

**Dennis A. Carson, M.D.,** Director, Moores UCSD Cancer Center **Ida Deichaite, Ph.D.,** Director, Industry Relations, Moores UCSD Cancer Center

Symposium Chair:

**David Cheresh, Ph.D.,** Associate Director for Translational Research and Professor of Pathology, Moores UCSD Cancer Center

Symposium Co-Chair:

**Catriona Jamieson, M.D., Ph.D.,** Director, Stem Cell Research Program, Assistant Professor of Medicine, Moores UCSD Cancer Center

8:00AM	Registration and Continental Breakfast
8:30AM	Welcome and Overview
	Dennis Carson, M.D., Director, Moores UCSD Cancer Center
8:45AM	<b><u>Chair</u> - David Cheresh, Ph.D.,</b> Associate Director for Translational Research and Professor of Pathology, Moores UCSD Cancer Center
	Co-Chair – Catriona Jamieson, M.D., Ph.D., Director, Stem Cell Research Program, Assistant Professor of Medicine, Moores UCSD Cancer Center
9:00AM	The Bedside to Bench Aspects of Clinical Research: The Cancer Immunotherapy Model Francesco P. Marincola, M.D., Chief, Infectious Disease and
	Immunogenetics Section, NIH
9:30AM	Development of Notch Pathway Inhibitors in Cancer
	Peter R. Strack, Ph.D., Research Fellow, Merck

10:15AM	Reversing MYC Induced Tumorigenesis
	Dean W. Felsher, M.D., Ph.D., Associate Professor of Medicine, Stanford School of Medicine
10:45AM	
	Addressing Drug Resistance in the Era of Targeted Anticancer Chemotherapy
	Frank Lee, Ph.D., Research Fellow, Oncology Drug Discovery, BMS
11:15AM	TSC-mTOR Pathway in Cell Growth and Cancer
	Kun-Liang Guan, Ph.D., Professor, Department of Pharmacology, Moores UCSD Cancer Center
11:45PM	Jole 2. Therementic Inhibiters
	Jak-2 Therapeutic Inhibitors
	<b>Richard M. Soll, Ph.D.,</b> Vice President, Research & Development, TargeGen
1:15PM	Lesson Learned: Biomarkers for Decision-Making in Oncology Clinical Trials
	Wendy Levin, M.D., Associate Director, Oncology, Translational Medicine, Pfizer
2:15PM	Hsp 90 Inhibitors in Cancer
	Chris Storgard, M.D., Director, Medical Research Oncology, Biogen Idec
2:45PM	
	Leukemia Specific Antigens - Their Roles in Pathogenesis and Potential for Use as Therapeutic Targets
	Thomas J. Kipps, M.D., Ph.D., Deputy Director, Professor of Medicine, Moores UCSD Cancer Center
3:30PM	<b>Panal</b> , "Translational research in academic and inductors
	Panel : "Translational research in academia and industry – identifying the common goals and potential areas of
	divergence – moving forward, what are the key parameters to

increasing the supply of innovative, effective, oncology therapies to the patient?"

<u>Panel moderator</u> – Ivor Royston, M.D., Managing Member, Forward Ventures

**Dennis A. Carson, M.D.,** Director, Moores UCSD Cancer Center

Thomas O. Daniel, M.D., President, Research, Celgene Corporation

**Richard Houghten, Ph.D.,** President, Torrey Pines Institute for Molecular Studies, Inc

**Francesco P. Marincola, M.D.,** Chief, Infectious Disease and Immunogenetics Section, NIH

John C. Reed, M.D., Ph.D., President and CEO, The Burnham Institute

Troy Wilson, Ph.D., J.D., President and CEO, Intellikine, Inc

4:30PM

Wine Reception